Popular topics to explore
India Pharma Market Grows 12.1% in July, Led by Zydus Lifesciences and Sun Pharma
SUNPHARMA India’s pharmaceutical market grew 12.1% year-on-year in July 2026, marking a strong recovery after subdued growth. According to Analyst latest note, the market has maintained double-digit growth, supported by price increases, n…
Update for investors of Emcure Pharma
EMCURE is currently trading at Rs. 1987.10, up by 10.00 points or 0.51% from its previous closing of Rs. 1977.10 on the BSE.
The scrip opened at Rs. 2007.65 and has touched a high and low of Rs. 2047.40 and Rs. 1,980.15 respectively. So…
Emcure Pharmaceuticals Shares in Focus After USFDA Inspection Closure
EMCURE Emcure Pharmaceuticals shares are likely to remain in focus on August 10 after the company received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for its formulations facility in Sanand, G…
Indian Market Insights – 10 August 2026
Indian equity markets are expected to remain in a consolidation phase with a neutral bias on the daily charts, while healthy sector rotation continues to support the broader market structure. The overall trend remains constructive, and a bu…
Emcure Pharma Receives US FDA Approval for Gujarat Plant
💊 EMCURE has received US FDA approval for its formulations manufacturing facility in Sanand, Gujarat, marking a significant regulatory milestone for the company. The approval strengthens Emcure's manufacturing capabilities and supports it…
Emcure Pharmaceuticals Q1 Profit Jumps 42% on Strong Revenue and Margin Growth
Research Analyst: UJVIN NEVATIA (PROPRIETOR: NEVAT INVESTMENTS) | SEBI Registration No.: INH100009628
EMCURE reported a robust performance for the first quarter of FY27, with consolidated net profit rising 42% year-on-year to ₹294 crore f…
Emcure Pharmaceuticals Q1 profit rises 36% at ₹292.5 crore
EMCURE Q1FY27 profit rises 36% on robust overseas growth, operating gains.
Emcure Pharmaceuticals reported a 36.2% YoY rise in Q1 FY27 net profit to Rs 292 crore, with revenue up 22.8% at Rs 2,580 crore and EBITDA margin expanding to 19.7%…
Emcure Pharma Delivers Strong Q1 on Overseas Growth
Emcure Pharmaceuticals reported a robust Q1 FY27, with net profit rising 36.2% YoY to ₹292 crore on the back of strong international business, higher operating leverage and productivity gains. Revenue increased 22.8% to ₹2,580 crore, while…
Emcure makes Gennova wholly-owned subsidiary for Rs. 2,318.7 Million
EMCURE has acquired the remaining 12.05% stake in Gennova Biopharmaceuticals for Rs. 2,318.7 Million, converting it into a wholly-owned subsidiary. The transaction involved 663,865 equity shares and was completed on July 21, 2026. Gennova…
22nd Jul · SEBI-Registered Analyst
The Central Pivot by Vineet Saxena (SEBI RA) · 22nd Jul
📈 Why Emcure Pharmaceuticals recently gained momentum?
Emcure Pharmaceuticals has received CDSCO approval to market Poviztra for the treatment of MASH (Metabolic Dysfunction-Associated Steatohepatitis) in adults with moderate to advanced liver fibrosis (F2–F3). This approval expands the use of…
Below are the top stock specific news we are tracking
ULTRACEMCO continues to target double-digit volume growth in FY27.
INDIGO InterGlobe Aviation (IndiGo) signed an MoU for 1,000 LEAP-1A engines with CFM.
PAYTM reported a strong Q1 with record profitability; board rejected the bonus…
EMCURE
* CDSCO Approval: Emcure Pharma can expand the use of Poviztra® (semaglutide) in India for treating adults with non-cirrhotic MASH and moderate-to-advanced liver fibrosis (F2–F3). * First-in-Class Opportunity: Innovator semaglutide become…
Emcure Pharmaceuticals Expands Liver Disease Treatment with CDSCO Approval for Poviztra
Emcure Pharmaceuticals Ltd has received approval from the Central Drugs Standard Control Organisation (CDSCO) to use its co-marketed brand Poviztra for the treatment of non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) i…
Expand the Use of Poviztra for MASH Indication Following CDSCO Approval - Emcure Pharmaceuticals Ltd
Code BSE: 544210 NSE: EMCURE
Emcure to Expand the Use of Poviztra for MASH Indication Following CDSCO Approval
The approval makes the innovator molecule from Novo Nordisk, the first and only GLP-1 receptor agonist approved in India fo…
Positive for Emcure
* CDSCO has approved Novo Nordisk’s Wegovy (semaglutide) as the first and only GLP-1 therapy in India for adults with metabolic dysfunction-associated steatohepatitis (MASH)/fatty liver disease with moderate-to-advanced fibrosis, expanding…
Gennova Biopharmaceuticals Divests mRNA Business for ₹1,395 Million
Gennova Biopharmaceuticals Limited (a subsidiary of Emcure Pharmaceuticals) has signed a Business Transfer Agreement on July 10, 2026, to execute a slump sale of its mRNA business to Immunoscript Life Science Private Limited for a lump sum…
Emcure unit sells mRNA business for ₹1,395 million
Gennova Biopharmaceuticals, a subsidiary of EMCURE sold its mRNA business to Immunoscript Life Science for ₹1,395 million. The deal, signed on July 10, 2026, is part of a strategic reorganization to focus on core biotechnology areas. The t…
BANSALWIRE
Bansal Wire Industries and Emcure Pharmaceuticals remained in focus on June 25 following major stake sales, with institutional investors emerging as key buyers in both companies. In Bansal Wire Industries, promoter group member Mrinaal Mitt…
EMCURE - A new ATH
EMCURE The breakout follows a prolonged phase of higher lows and accumulation, signaling renewed institutional buying interest and continuation of the primary uptrend.
Mixed Signals LIC Hit by Leadership Exit, Block Deals Lift Realty & Pharma
Market action was driven by stock-specific developments as Life Insurance Corporation of India declined around 3% following the resignation of its CFO, raising concerns over near-term management continuity. In contrast, LODHA and EMCURE g…
